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At the rat neuromuscular junction, adenosine acts as a
neuromodulator either inhibiting (via A1 receptors) or
facilitating (via A2A receptors) the release of acetylcholine
(ACh) from motor nerve endings (Correia-de-Sá et al.
1991; reviewed by Ribeiro et al. 1996). The effect of
endogenous extracellular adenosine depends on the
pattern of nerve stimulation: at low stimulation
frequencies there is a predominant tonic inhibition
mediated by A1 receptors, whereas with increasing
frequencies adenosine facilitates ACh release through
tonic activation of A2A receptors (Correia-de-Sá et al.
1996). Interestingly, which adenosine receptor is
predominantly activated is apparently determined by the
differential contribution of the two main pathways leading
to extracellular adenosine accumulation (Correia-de-Sá et
al. 1996; Cunha et al. 1996a). Indeed, adenosine can either
be released as such or can be formed upon the sequential
extracellular dephosphorylation of released ATP
(reviewed in Cunha, 2001a).
ATP contained in synaptic vesicles is released from
stimulated nerve terminals as well as from the activated
postsynaptic components (reviewed in Bodin &
Burnstock, 2001). Once released, ATP can act as a fast
neurotransmitter in some synapses or as a presynaptic
neuromodulator (reviewed in Cunha & Ribeiro, 2000).
Most commonly, released ATP is metabolised
extracellularly into adenosine by a cascade of ecto-
nucleotidases (reviewed in Cunha, 2001b). For the
convenience of the reader, the pathways responsible for
the extracellular catabolism of ATP and adenosine as well
as the sites of action of various inhibitors are depicted in
Fig. 1. With increasing frequencies of nerve stimulation,
there is an increased contribution of ATP-derived
adenosine (Cunha et al. 1996b). Since ATP is released in a
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At synapses, ATP is released and metabolised through ecto-nucleotidases forming adenosine, which
modulates neurotransmitter release through inhibitory A1 or facilitatory A2A receptors, according
to the amounts of extracellular adenosine. Neuromuscular junctions possess an ecto-AMP
deaminase that can dissociate extracellular ATP catabolism from adenosine formation. In this study
we have investigated the pattern of ATP release and its conversion into adenosine, to probe the role
of ecto-AMP deaminase in controlling acetylcholine release from rat phrenic nerve terminals.
Nerve-evoked ATP release was 28 ± 12 pmol (mg tissue)_1 at 1 Hz, 54 ± 3 pmol (mg tissue)_1 at 5 Hz
and disproportionally higher at 50 Hz (324 ± 23 pmol (mg tissue)_1). Extracellular ATP (30 mM)
was metabolised with a half time of 8 ± 2 min, being converted into ADP then into AMP. AMP was
either dephosphorylated into adenosine by ecto-5‚-nucleotidase (inhibited by ATP and blocked by
200 mM a,b-methylene ADP) or deaminated into IMP by ecto-AMP deaminase (inhibited by
200 mM deoxycoformycin, which increased adenosine formation). Dephosphorylation and
deamination pathways also catabolised endogenously released adenine nucleotides, since the nerve-
evoked extracellular AMP accumulation was increased by either a,b-methylene ADP (200 mM) or
deoxycoformycin (200 mM). In the presence of nitrobenzylthioinosine (30 mM) to inhibit adenosine
transport, deoxycoformycin (200 mM) facilitated nerve-evoked [3H]acetylcholine release by
77 ± 9 %, an effect prevented by the A2A receptor antagonist, ZM 241385 (10 nM). It is concluded
that, while ecto-5‚-nucleotidase is inhibited by released ATP, ecto-AMP deaminase activity
transiently blunts adenosine formation, which would otherwise reach levels high enough to activate
facilitatory A2A receptors on motor nerve terminals.
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frequency-dependent manner (Silinsky, 1975; Wieraszko
et al. 1989; Cunha & Sebastião, 1993; Cunha et al. 1996b), it
can reach levels high enough to inhibit ecto-5‚-
nucleotidase, the enzyme that forms adenosine from
released adenine nucleotides (discussed in Cunha, 2001b).
Under these conditions, there is a delayed burst-like
formation of adenosine leading to high synaptic
concentrations of the nucleoside similar to those required
to activate facilitatory A2A receptors (Correia-de-Sá et al.
1996; Cunha et al. 1996a; reviewed by Cunha, 2001a,b).
However, the relation between ATP release and adenosine
receptor activation at the neuromuscular junction is
complicated by the observation that AMP can also be
extracellularly deaminated (Alertsen et al. 1958; Cunha &
Sebastião, 1991) into the inactive metabolite IMP (e.g.
Ribeiro & Sebastião, 1987), therefore bypassing adenosine
formation. Understanding the effective contribution of
this shunt-like deamination pathway is of central
importance to predict when the neuromodulatory role of
adenosine will shift from inhibition to facilitation with
increasing frequencies of motoneuronal firing.
In the present work, we studied the pattern of ATP release
and its extracellular catabolism with particular emphasis
on the relative contribution of ecto-5‚-nucleotidase
(forming adenosine) and of ecto-AMP deaminase
(bypassing adenosine formation) pathways. We then used
a pharmacological strategy to block ecto-AMP deaminase
to probe the importance of this shunt-like pathway for the
tonic adenosine modulation of ACh release.
METHODS 
Experimental preparation
Rats (Wistar, 150–200 g) of either sex (Charles River, Barcelona,
Spain) were kept at a constant temperature (21 ° C) and a regular
light (06.30–19.30 h) dark (19.30–06.30 h) cycle with food and
water provided ad libitum. The animals were decapitated and
exsanguinated under halothane anaesthesia, according to the
Portuguese and EU guidelines for handling and use of
experimental animals. All experiments were conducted using left
phrenic nerve–hemidiaphragm preparations (6–8 mm width)
(see Correia-de-Sá et al. 1996). The preparations were mounted in
2 ml chambers, with direct oxygenation (95 % O2 and 5 % CO2),
kept at 37 °C, and superfused (3 ml min_1) with gassed Tyrode
solution containing (mM): NaCl 137.0, KCl 2.7, CaCl2 1.8, MgCl2
1.0, NaH2PO4 0.4, NaHCO3 11.9, and glucose 11.2. The nerve was
then drawn into a suction electrode for stimulation. The tissue was
allowed to equilibrate, under superfusion with gassed Tyrode
solution, for 30 min.
Kinetic experiments
For kinetic experiments of purine catabolism, after the 30 min
equilibration period, the bath was emptied and 2 ml of a
3–100 mM solution of the chosen initial substrate in Tyrode
solution at 37 °C was added to the preparations at zero time.
Samples of 75 ml were collected from the bath at different times up
to 45 min for HPLC analysis of the variation of substrate
disappearance and product formation (see Fig. 1) (Cunha &
Sebastião, 1991; Salgado et al. 2000). When the modification of
the extracellular catabolism of an initial substrate by an inhibitor
was tested, the preparations were first incubated for at least
15 min with the modifiers before starting the kinetic experiment
still in the presence of the modifier (see Cunha & Sebastião, 1991).
In all experiments, the concentration of products at the different
times of sample collection was corrected by subtracting the
concentration of products in samples collected from the same
preparation incubated without adding substrate. Only IMP,
inosine and hypoxanthine were spontaneously released from the
preparations in concentrations that did not exceed 1.4 mM.
[3H]Acetylcholine release experiments
The procedures used for labelling the preparations and measuring
evoked [3H]acetylcholine ([3H]ACh) release have been previously
described (Correia-de-Sá et al. 1991; 1996) and were used with
minor modifications. Experiments were performed in the absence
of cholinesterase inhibitors to prevent non-physiological
extracellular accumulation of acetylcholine that might exaggerate
cholinergic neuromodulation (cf. Correia-de-Sá & Ribeiro,
1994a; Oliveira et al. 2002). After a 30 min equilibration period,
the superfusion was stopped and the nerve endings were labelled
for 40 min with 1 mM [3H]choline (specific activity
2.5 mCi nmol_1) under electrical stimulation at 1 Hz. After the end
of the labelling period, the preparations were again superfused
(15 ml min_1) and the nerve stimulation stopped. From this time
onwards, hemicholinium-3 (10 mM) was present to prevent
uptake of choline. After a 60 min period of washout, bath samples
(2 ml) were automatically collected every 3 min by emptying and
refilling the organ bath with the solution in use, using a fraction
collector (Gilson, FC 203B, France) coupled to a peristaltic pump
(Gilson, Minipuls3, France) programmed device. Aliquots
(0.5 ml) of the incubation medium were added to 3.5 ml of
Packard Insta Gel II (USA) scintillation cocktail. Tritium content
of the samples was measured by liquid scintillation (counting
efficiency of 40 ± 2 %) after appropriate background subtraction,
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Figure 1. Schematic representation of the extracellular
catabolism of ATP and adenosine
The solid arrows indicate the enzymatic activities identified.
Dotted arrows represent inhibition of the ecto-5‚-nucleotidase
activity by ATP and ADP. The numbers in the figure represent: 1,
ecto-5‚-nucleotidase; 2, ecto-AMP deaminase; 3, ecto-adenosine
deaminase; 4, adenosine transporter. The lightning-like arrows
indicate the enzymatic activities that are the main targets of the
indicated drugs (AOPCP, a,b-methylene ADP; dCOF,
deoxycoformycin; ENHA, erythro-9-(2-hydroxy-3-
nonyl)adenine; NBTI, S-(p-nitrobenzyl)-6-thioinosine). Note that
dCOF also inhibits adenosine deaminase as well as adenosine
transporters, EHNA inhibits adenosine deaminase, and AOPCP
inhibits both the dephosphorylation of AMP as well as that of IMP.
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which did not exceed 5 % of the tritium content of the samples.
The radioactivity was expressed as disintegrations per minute
(DPM) per gram wet weight of the tissue determined at the end of
the experiment. After the loading and washout periods, the
preparations contained (5542 ± 248) w 103 DPM g_1 and the
resting release was (132 ± 12) w 103 DPM g_1 in 3 min (n = 8).
When the fractional release was calculated, this value was
2.38 ± 0.14 % of the radioactivity present in the tissue in the first
collected sample.
Release of [3H]ACh was evoked by electrical stimulation of the
phrenic nerve with 5 Hz frequency trains applied over 2.5 min.
Supramaximal intensity rectangular pulses of 40 ms duration and
a current strength of 8 mA were used. This was done to achieve
synchronisation of phrenic motoneuron firing in order to reduce
the number of silent units. Pulses were generated by a Grass S48
(USA) stimulator coupled to a stimulus isolation unit (Grass
SIU5) operating in a constant current mode. The stimulation
parameters were continuously monitored on an oscilloscope
(Meguro, MO-1251A, Japan). Two stimulation periods were
used: at 12 min (S1) and at 39 min (S2) after the end of washout
(zero time). Electrical stimulation of the phrenic nerve increased
only the release of [3H]ACh in a Ca2+- and tetrodotoxin-sensitive
manner (Correia-de-Sá et al. 2000), while the output of
[3H]choline remained unchanged during the stimulation periods
(Wessler & Kilbinger, 1986). Therefore, the evoked release of
[3H]ACh was calculated by subtracting the basal tritium outflow
from the total tritium outflow during the stimulation period (cf.
Correia-de-Sá et al. 1996).
Test drugs were added 15 min before S2 and were present up to the
end of the experiments. The change in the ratio between the
evoked [3H]ACh released during the two stimulation periods
(S2/S1) relative to that observed in control situations (in the
absence of test drugs) was taken as a measure of the effect of the
tested drugs. When we evaluated the modifications of the effect of
tested drugs by a modifier, this modifier was applied 15 min
before starting sample collection and hence was present during S1
and S2. When present during S1 and S2, none of the tested
modifiers significantly altered (P > 0.05) the S2/S1 ratio as
compared to the S2/S1 ratio obtained in the absence of the
modifiers (data not shown).
Release of ATP and of adenine nucleotides
For the ATP release experiments or to follow the nerve-evoked
release of adenine nucleotides, after the 30 min equilibration
period, the preparations were incubated as for the release of
[3H]ACh, except that no [3H]choline was added to the Tyrode
solution, although the 30 min prestimulation period (simulating
loading) was maintained. The preparations were then superfused
(3 ml min_1) for 60 min with gassed Tyrode solution containing
hemicholinium-3 (10 mM) that was present from then on. After
stopping superfusion, bath samples (1.2 ml) were collected every
2.5 min by emptying and refilling the organ bath with the solution
in use. As for the release of [3H]ACh, the preparations were also
stimulated twice using similar nerve stimulating conditions.
When using the 5 Hz protocol, stimulation was delivered at a
frequency of 5 Hz in two 2.5 min periods, at 7.5 min (S1) and at
32.5 min (S2) after starting sample collection (zero time). When
using the 1 Hz protocol, stimulation was delivered at a frequency
of 1 Hz in two 12.5 min periods, at 7.5 min (S1) and at 32.5 min
(S2) after starting sample collection (zero time). When using the
50 Hz protocol, stimulation was delivered at a frequency of 50 Hz
in two 15 s periods, at 7.5 min (S1) and at 32.5 min (S2) after
starting sample collection (in this particular protocol, the bathing
medium was changed immediately after stopping the application
of the pulse). In these three protocols (where the number of pulses
was kept constant), only the sample collected before stimulus
application and the sample collected immediately after
stimulation, were retained for analysis.
Aliquots of 250 ml of each sample were used for the luminometric
assay of ATP conducted with the luciferin–luciferase assay (see
Cunha et al. 1996b). To measure AMP by reverse-phase HPLC, we
used 200 ml aliquots from collected samples (see Cunha &
Sebastião, 1993). Nerve-evoked release of ATP (or adenine
nucleotides) was calculated by subtracting the basal release,
measured in the sample collected before stimulation, from the
total release of ATP (or adenine nucleotides) determined after
stimulus application. When testing the ability of a modifier to
affect ATP or adenine nucleotide release, this modifier was added
to the bath 15 min before starting sample collection and was
present throughout the protocol.
Reagents
ATP, ADP, AMP, IMP, adenosine, inosine, a,b-methylene ADP
(AOPCP), S-(p-nitrobenzyl)-6-thioinosine (NBTI), hemi-
cholinium-3, tetrodotoxin, luciferin and luciferase (ATP assay
mix) were from Sigma Ibérica, 1,3-dipropyl-8-cyclopenthyl-
xanthine (DPCPX) was from Research Biochemicals Inc. (Sigma
Ibérica), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) was
from Burroughs Wellcome, dipyridamole was from Boehringer
Ingelheim (Germany), 4-(2-[7-amino-2-(2-furyl) (1,2,4)tria-
zolo(2,3-a)(1,3,5)triazin-5-ylamino]ethyl)phenol (ZM 241385)
was from Tocris Cookson (UK), [methyl-3H]choline chloride
(80 Ci mmol_1) was from Amersham (Pharmacia, Portugal) and
deoxycoformycin was from Parke-Davies.
Dipyridamole, EHNA, NBTI, deoxycoformycin and ZM241385
were made up to a 5 mM stock solution in dimethylsulfoxide and
DPCPX was made up into 5 mM stock in 99 % dimethylsulfoxide
and 1 % NaOH (1 M). These stock solutions were aliquoted and
stored at _20 °C and aqueous dilution of these solutions was made
daily.
Statistics
The values are presented as means ± S.E.M. To test the significance
of the effect of drugs versus control, Student’s paired t test was
used. When making comparisons from a different set of
experiments with control, one way analysis of variance (ANOVA)
followed by Dunnett’s test was used. P < 0.05 was considered to
represent a significant difference.
RESULTS
ATP release
Stimulation of the phrenic nerve at a frequency of 5 Hz for
2.5 min led to an increased accumulation of ATP in the
bath effluent from an average basal value of 21 ± 3 pmol
(mg tissue)_1 to a total value of 75 ± 5 pmol (mg tissue)_1
(n = 6). As illustrated in Fig. 2, this evoked release of ATP
was frequency dependent, increasing sharply upon high
frequency stimulation (50 Hz). Nerve-evoked release of
ATP was Ca2+ dependent, since omission of Ca2+ in the
Tyrode solution essentially abolished the ATP outflow
(n = 4) and was dependent on neuronal activity since it
was nearly abolished by 1 mM tetrodotoxin (n = 3).
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Extracellular catabolism of ATP and formation of
adenosine
We then investigated the fate of extracellular ATP in
phrenic nerve–hemidiaphragm preparations. As illustrated
in Fig. 3, extracellular ATP (30 mM) was catabolised with a
half-degradation time of 8 ± 2 min (n = 8). The ATP
metabolites detected in the bath were ADP, whose
concentration reached a maximum of 5.4 ± 0.1 mM at
30 min, AMP, whose concentration reached a maximum
of 3.2 ± 0.7 mM at 45 min, adenosine, whose maximum
concentration (5.7 ± 1.5 mM) was reached at 45 min, and
IMP, whose maximum concentration (2.0 ± 0.6 mM) was
reached at 45 min. Surprisingly, the accumulation of IMP
was preferential during the first 5 min; beyond this period,
the speed of IMP accumulation tapered while adenosine
concentration progressively increased. This pattern of
extracellular catabolism of ATP was similar to that
described in other neuromuscular junctions (e.g. Manery
& Dryden, 1979; Cunha & Sebastião, 1991; but see Vizi et
al. 2000) and differed from that found in the central
nervous system, where no deamination metabolites of
adenine nucleotides (like IMP) were found (reviewed in
Cunha, 2001b). Therefore, we investigated in more detail
the pattern of extracellular catabolism of AMP, using
selective inhibitors of both dephosphorylation and
deamination pathways.
As shown in Fig. 4A, extracellular AMP (30 mM) was
catabolised with a half-degradation time of 23 ± 5 min
(n = 12). The concentration of AMP metabolites detected
in the bath rose almost linearly with time up to 45 min.
The metabolites identified were adenosine, which reached
a maximum concentration of 14.3 ± 1.8 mM; IMP, which
reached a maximum concentration of 5.3 ± 0.9 mM; and
inosine, which reached a maximum concentration of
14.5 ± 1.1 mM. As expected, dephosphorylation of AMP
(30 mM) leading to adenosine formation was more
effective than AMP deamination forming IMP during the
whole assay (inosine was not considered in this comparison
since it can be formed both from the dephosphorylation of
IMP and from the intra- and/or extracellular deamination
of adenosine, see Fig. 1 and text below).
As shown in Fig. 4B, the ecto-5‚-nucleotidase inhibitor,a,b-methylene ADP (200 mM) (Naito & Lowenstein,
1985), essentially prevented the formation of adenosine
from exogenously added AMP. Under these conditions,
there was a decrease in the extracellular catabolism of AMP
since only 37.3 ± 1.0 % of the initial amount of AMP
added at time zero was extracellularly metabolised after
45 min (n = 4). In the presence of a,b-methylene ADP
(200 mM), the AMP-derived IMP formation was slightly
(P > 0.05) enhanced, since IMP reached a maximal
concentration of 8.4 ± 2.4 mM at 45 min. This is probably
due to the blockade of IMP dephosphorylation to inosine,
since both AMP and IMP are dephosphorylated by ecto-
5‚-nucleotidase, i.e. the extracellular catabolism of IMP is
nearly blocked by 200 mM a,b-methylene ADP (data not
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Figure 2. The amount of ATP released upon stimulating
the phrenic nerve depends on the stimulus frequency
The ordinates represent the evoked release of ATP, quantified in
the effluent with the luciferin–luciferase assay, upon application of
electrical stimulation through the phrenic nerve trunk using
different frequencies of stimulation (1–50 Hz) while keeping the
number of pulses constant. Nerve-evoked release of ATP was
calculated by subtracting the basal release from the total release of
ATP determined after stimulus application. The data are
means ± S.E.M. of 4–6 experiments.
Figure 3. Time course of extracellular ATP metabolism
ATP (30 mM) was added at zero time to the preparation and
samples were collected from the bath at the times indicated on the
abscissa. Each collected sample was analysed by HPLC to separate
and quantify A, ATP (•) and its metabolites and B, ADP (8), AMP
(0), IMP (6) and adenosine (1). Inosine was also detected but is
not presented for the sake of clarity. To quantify the spontaneous
release of purines, samples were also collected from the bath at the
same time indicated on the abscissa adding a solution without ATP
at zero time. The data are means ± S.E.M. of 8 experiments.
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shown). The ability of a,b-methylene ADP to inhibit ecto-
5‚-nucleotidase is due to the known capacity of adenine
nucleotides, namely ATP and ADP, to inhibit ecto-5‚-
nucleotidase activity (Naito & Lowenstein, 1985; Cunha,
2001b). This inhibition can be evaluated by quantifying
the ratio ([AMP] + [IMP])/([adenosine] + [inosine]),
which is an inverse measure of the activity of ecto-5‚-
nucleotidase (Cunha & Sebastião, 1991; Cunha, 2001b).
When adding as an initial substrate 30 mM of either ATP,
ADP or AMP, this ratio at 45 min was 1.10 ± 0.21 (n = 8)
for ATP, 1.00 ± 0.14 (n = 6) for ADP and 0.45 ± 0.06
(n = 12) for AMP, confirming that ATP and ADP
inhibited ecto-5‚-nucleotidase in phrenic nerve
hemidiaphragm preparations. The inhibition of ecto-5‚-
nucleotidase by ATP can be exaggerated by incubating the
preparations with a higher concentration (100 mM) of
ATP. In such conditions, the hydrolysis of ATP is delayed,
as indicated by a significant (P < 0.05) increase in the
nucleotides/nucleosides ratio to 2.89 ± 0.46 (n = 3). In
contrast, this ratio was not significantly altered (P > 0.05)
when the initial concentration of AMP was increased to
100 mM (0.57 ± 0.09, n = 3).
The ecto-AMP deaminase inhibitor, deoxycoformycin
(200 mM) (Agarwal & Parks, 1977), essentially prevented
the formation of IMP from exogenously added AMP
(Fig. 4C). Under these conditions, there was a decrease in
the extracellular catabolism of AMP that was now
metabolised with a half-degradation time of 39 ± 6 min
(n = 4). In the presence of deoxycoformycin (200 mM), the
AMP-derived adenosine formation was slightly (P > 0.05)
enhanced, since adenosine now reached a maximal
concentration of 19.0 ± 4.0 mM at 45 min. This tendency
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Figure 4. Extracellular catabolism of AMP in the absence and in the presence of the ecto-5‚-
nucleotidase inhibitor, a,b-methylene ADP (AOPCP, 200 mM), and/or of the AMP deaminase
inhibitor, deoxycoformycin (dCOF, 200 mM)
A, the pattern of extracellular AMP metabolism in the rat innervated hemidiaphragm preparation. AMP
(30 mM) was added at zero time to the preparation. Bath samples were collected at the times indicated on the
abscissa, for HPLC analysis to separate and quantify AMP (0) and its metabolites, IMP (6), adenosine (1)
and inosine (7). Samples were also collected from the bath at the same time indicated on the abscissa but
adding a solution without AMP at zero time to quantify the spontaneous release of purines at the different
time points. The data are means ± S.E.M. of 12 experiments. B, a similar time course of extracellular
catabolism of AMP, but now in the presence of AOPCP (200 mM). There is an impairment of the extracellular
conversion of AMP into adenosine whereas there is a relative increase in the conversion of AMP into IMP.
The data are means ± S.E.M. of 4 experiments. C, a similar time course of catabolism of extracellular AMP, but
in the presence of dCOF (200 mM). It is evident that there is an impairment of the extracellular conversion of
AMP into IMP and an increase in the effectiveness of the conversion of AMP into adenosine. The data are
means ± S.E.M. of 4 experiments. D, the near-complete blockade of the extracellular catabolism of AMP in
the simultaneous presence of AOPCP (200 mM) and dCOF (200 mM). The data are means ± S.E.M. of 4
experiments. All the experiments were performed in the presence of NBTI (30 mM) to block adenosine
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for the extracellular concentration of adenosine to increase
results both from the greater availability of AMP as a
substrate of ecto-5‚-nucleotidase, and from the ability of
deoxycorformycin to inhibit the removal of extracellular
adenosine, namely through adenosine transporters (Rogler-
Brown & Parks, 1980) and through adenosine deaminase
(Agarwal & Parks, 1977). In fact, in experiments designed to
follow the time course of extracellular adenosine removal, it
was confirmed that the conversion of adenosine into inosine
was attenuated by deoxycoformycin (n = 6, data not shown).
The removal of extracellular adenosine was inhibited by an
inhibitor of adenosine transport, S-(p-nitrobenzyl)-6-
thioinosine (NBTI, 5 mM, 36 ± 5 % inhibition, n = 5), and
further inhibited by an inhibitor of adenosine deaminase,
erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA, 25 mM,
26 ± 3 % inhibition, n = 5), indicating that both adenosine
uptake and ecto-adenosine deaminase might be involved
in the clearance of extracellular adenosine at the rat
neuromuscular junction as predicted from functional
studies (Correia-de-Sá & Ribeiro, 1996).
Finally, as shown in Fig. 4D, the simultaneous presence ofa,b-methylene ADP (200 mM) and of deoxycoformycin
(200 mM) virtually prevented the extracellular catabolism
of AMP.
Relative contribution of the ecto-AMP deaminase
pathway for adenosine formation
To demonstrate that the two alternative pathways of
extracellular metabolism of AMP also contributed to the
removal of endogenously released adenine nucleotides, we
tested the effect of a,b-methylene ADP (200 mM) and/or
deoxycoformycin (200 mM) on the accumulation of
adenine nucleotides triggered by stimulating the phrenic
nerve. We quantified the released adenine nucleotides as
AMP accumulating in the extracellular milieu, since we
have pharmacological tools to interfere with the
extracellular catabolism of AMP, but not with that of ATP.
As illustrated in Fig. 5, we could not detect a nerve-evoked
accumulation of endogenous AMP in the absence of any
inhibitor of extracellular AMP catabolism. This suggests
that the rate of extracellular catabolism of endogenously
formed AMP is larger than that of exogenously added
AMP, in accordance with the hypothesis that the ecto-
nucleotidase pathway displays channelling properties
(reviewed in Cunha, 2001b). However, when we blocked
either the ecto-AMP deaminase activity, with
deoxycoformycin (200 mM, n = 4), or the ecto-5‚-
nucleotidase, with a,b-methylene ADP (200 mM, n = 5),
we now observed a net evoked accumulation of
endogenous extracellular AMP. Interestingly, we found
that these two inhibitors of extracellular AMP catabolism
increased the total accumulation of extracellular AMP in a
manner similar to the basal accumulation of extracellular
AMP (Fig. 5). This indicates that both ecto-AMP
deaminase and ecto-5‚-nucleotidase control both the basal
and the total accumulation of endogenous extracellular
AMP on nerve stimulation (Fig. 5). Simultaneous
application of the two inhibitors did not cause an
accumulation of the evoked endogenous extracellular
AMP (1.15 ± 0.11 nmol (g tissue)_1, n = 6) that was
significantly (P > 0.05) higher than that caused by 200 mMa,b-methylene ADP (1.09 ± 0.33 nmol (g tissue)_1,
n = 5), though it was greater than that caused by 200 mM
deoxycoformycin (0.58 ± 0.14 nmol (g tissue)_1, n = 4).
These observations suggest that endogenous extracellular
AMP is catabolised more efficiently by ecto-5‚-
nucleotidase than by ecto-AMP deaminase. These results
fully agree with our findings measuring the extracellular
catabolism of exogenously added AMP (see Fig. 4A),
where dephosphorylation of AMP leading to adenosine
formation was preferential as compared with the
generation of its inactive metabolite, IMP (e.g. Ribeiro &
Sebastião, 1987), via the ecto-AMP deaminase pathway.
Contribution of the ecto-AMP deaminase pathway
for adenosine modulation of ACh release
We have previously documented the physiological
relevance of ecto-5‚-nucleotidase on the evoked
acetylcholine (ACh) release from phrenic nerve terminals
(Correia-de-Sá et al. 1996; Cunha et al. 1996a), which is
under dual control of inhibitory A1 receptors and
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Figure 5. Extracellular accumulation of released adenine
nucleotides is controlled by the activities of both ecto-5‚-
nucleotidase and ecto-AMP deaminase
AMP was quantified by HPLC in bath samples collected after
2.5 min incubation with the preparations during rest (basal) or
after electrical stimulation (total) of the phrenic nerve trunk with
5 Hz trains. The ecto-5‚-nucleotidase inhibitor, a,b-methylene
ADP (AOPCP, 200 mM), and/or the ecto-AMP deaminase
inhibitor, deoxycoformycin (dCOF, 200 mM), were added to the
incubation medium 15 min before sampling. The absence (_) or
presence (+) of each drug is indicated below each bar. T he evoked
release of adenine nucleotides (evoked) was calculated by
subtracting the basal release from the total release of adenine
nucleotides. The data are means ± S.E.M. of 3–8 experiments.
* P < 0.05 when compared with 0 nmol (mg tissue)_1; ** P < 0.05
when compared with the effect of either AOPCP or dCOF alone;
*** P < 0.05 between the indicated bars. 
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facilitatory A2A receptors depending on the levels of
extracellular adenosine (Correia-de-Sá & Ribeiro, 1996).
We have reported that prevention of ATP-derived
adenosine formation with a,b-methylene ADP (200 mM)
caused an inhibition of the evoked release of [3H]ACh and,
in addition, we pharmacologically confirmed that this was
due to removal of tonic activation of facilitatory A2A
receptors (Cunha et al. 1996a). These findings indicated
that adenosine originating from catabolism of adenine
nucleotides preferentially activates facilitatory A2A
receptors in motor nerve terminals. As we have now found
that ecto-AMP deaminase also contributed to the removal
of endogenous extracellular AMP, we tested the functional
impact of the blockade of ecto-AMP deaminase on the
nerve-evoked release of [3H]ACh. The experiments were
performed in the presence of a supramaximal
concentration of an inhibitor of adenosine transport,
NBTI (30 mM) (see Correia-de-Sá & Ribeiro, 1996), since
deoxycoformycin has previously been shown to inhibit
adenosine transporters (e.g. Rogler-Brown & Parks, 1980).
In these conditions, deoxycoformycin (200 mM) facilitated
the evoked [3H]ACh release by 77 ± 9 % (n = 7).
Deoxycoformycin-induced facilitation of [3H]ACh release
was not related to the modulation of [3H]ACh release via
adenosine A1 receptors, since the facilitatory effect of
deoxycorformycin was essentially maintained (58 ± 8 %
facilitation, n = 4) in the presence of the selective A1
receptor antagonist, 1,3-dipropyl-8-cyclopenthylxanthine
(DPCPX, 2.5 nM) (Fig. 6). Instead, facilitation of [3H]ACh
caused by deoxycorformycin (200 mM) was due to the
activation of adenosine A2A receptors, since the selective
A2A receptor antagonist, ZM 241385 (10 nM), completely
prevented this facilitatory effect. In fact, upon blockade of
A2A receptors with ZM 241385 (10 nM), deoxycorformycin
(200 mM) now inhibited the evoked release of [3H]ACh by
33 ± 8 % (n = 4) (see Fig. 6). This was predicted since the
blockade of facilitatory A2A receptors might exaggerate
inhibition of ACh release operated by the activation of
inhibitory A1 receptors. These findings are in good
agreement with the previously reported A1/A2A inter-
receptor equilibrium controlling ACh release evoked by
5 Hz trains (Pereira et al. 2000), which tightly depends on
the extracellular levels of adenosine (Correia-de-Sá &
Ribeiro, 1996; Correia-de-Sá et al. 1996).
DISCUSSION
The present results confirm that adenine nucleotides,
namely ATP, are released to the extracellular milieu upon
stimulation of motor nerve endings and that they are
metabolised extracellularly by a series of ecto-
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Figure 6. Blockade of ecto-AMP deaminase with deoxycoformycin (200 mM) leads to the
facilitation of evoked acetylcholine (ACh) release through the activation of facilitatory A2A
adenosine receptors
The evoked release of [3H]ACh was elicited by two stimulation periods of the phrenic nerve (S1 and S2,
separated by 27 min) with a frequency of 5 Hz and 750 supramaximal intensity pulses of 40 ms duration.
Deoxycoformycin (dCOF, 200 mM) was added from 15 min before S2 onwards. When the effect of dCOF was
tested in the presence of the selective adenosine A2A receptor antagonist, ZM 241385 (10 nM), or the selective
adenosine A1 receptor antagonist, DPCPX (2.5 nM), these antagonists were added 15 min before starting
sample collection (present during S1 and S2). The absence (_) or presence (+) of each drug during S2 or
during S1 and S2 is indicated below each bar. The ordinates are percentage changes in the S2/S1 ratios as
compared with the S2/S1 ratios in control experiments. Zero percent represents identity between the two
ratios; positive and negative values represent facilitation or inhibition of the evoked release of [3H]ACh,
respectively. The results are means ± S.E.M. of 4–7 experiments. * P < 0.05 when compared with controls;
** P < 0.05 when compared with the effect of deoxycoformycin in the absence of adenosine receptor
antagonists. Note that the inhibitor of adenosine transporters, nitrobenzylthioinosine, was present in a
supramaximal concentration (30 mM) in all superfusion solutions.
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nucleotidases (see Fig. 1 for a schematic representation).
The activity of the ecto-nucleotidase pathway appears
critical to define the pattern of formation of extracellular
ATP-derived adenosine to allow the activation of either
inhibitory A1 or facilitatory A2A adenosine receptors. In
particular, the neuromuscular junction is equipped with
an ecto-AMP deaminase pathway that metabolises
adenine nucleotides bypassing adenosine formation, and
this activity is critical to divert part of the released adenine
nucleotides from adenosine formation. Thus, while the
ecto-5‚-nucleotidase pathway modulates the rate of
adenosine formation from released nucleotides,
alternative AMP deamination controls the amount of
AMP available to be converted into adenosine. The
combined effect of both pathways might serve to maintain
the local concentration of adenosine at lower levels
allowing the predominant activation of inhibitory A1
receptors to operate at moderate frequencies of nerve
stimulation (e.g. 5 Hz trains) (see Correia-de-Sá &
Ribeiro, 1996).
Several studies using neuromuscular junctions from
different species and different stimulation patterns have
concluded that nerve stimulation triggers the release of
ATP (Silinsky, 1975; Smith, 1991; Silinsky & Redman,
1996; Vizi et al. 2000). There is some debate as to whether
this released ATP originates from nerve terminals (e.g.
Silinsky, 1975), from activated muscle fibres (e.g. Smith,
1991; Vizi et al. 2000) or from peri-synaptic Schwann cells
(discussed in Fields & Stevens, 2000). But, irrespective of
the source of ATP released upon stimulating motor nerve
terminals, the relevant question from the functional point
of view is what might be the role of extracellular ATP in the
control of neuromuscular transmission. Although some
reports support possible direct effects of ATP as such
(Giniatullin & Sokolova, 1998; Salgado et al. 2000;
Deuchars et al. 2001; Galkin et al. 2001), the most likely
role for extracellular ATP is to act as a source of adenosine
that fulfils a key neuromodulatory role in the control of
neuromuscular transmission through activation of
inhibitory A1 or facilitatory A2A receptors (Ribeiro &
Walker, 1975; Correia-de-Sá et al. 1991, 1996; Cunha et al.
1996a; Silinsky et al. 1999). This contention obviously
places greater emphasis on the understanding of the
enzymes responsible for the extracellular metabolism of
ATP into adenosine, generically named ecto-
nucleotidases.
The extracellular ATP hydrolysis at neuromuscular
junctions shares many similarities with that described in
many different preparations, being mainly catalysed by an
ATP and/or ADP metabolising enzyme(s) and an ecto-5‚-
nucleotidase designed to form adenosine (reviewed in
Zimmermann & Braun, 1999; Cunha, 2001b). The main
difference found at neuromuscular junctions is the
presence of an ecto-AMP deaminase activity that converts
AMP into IMP (see Fig. 1), which has been reported to be
present at various neuromuscular junctions (Manery &
Dryden, 1979; Cunha & Sebastião, 1991). Skeletal muscle
fibres are one of the mammalian tissues with higher
activity of AMP deamination (Ogasawara et al. 1974).
Most of this enzymatic activity is associated with muscle
fibres, but it is also present in the vicinity of neuronal and
circulatory elements (Thompson et al. 1992), although it is
not known if AMP deaminase might also be located
presynaptically. We have now confirmed that the AMP
deaminase involved in the extracellular catabolism of
adenine nucleotides at the innervated hemidiaphragm is
indeed an ecto-nucleotidase (see also Alertsen et al. 1958).
The expected role of this ecto-AMP deaminase activity
might be to divert released adenine nucleotides from
extracellular adenosine formation, since AMP is
inactivated into IMP (and inosine) rather than
dephosphorylated into adenosine. In fact, the extracellular
accumulation of endogenous adenine nucleotides is
increased by deoxycoformycin. Likewise, the kinetic
experiments comparing the pattern of extracellular
adenosine formation upon addition of AMP as initial
substrate show a more than 50 % increase in the amounts
of extracellular adenosine formed in the presence of the
ecto-AMP deaminase inhibitor, deoxycoformycin,
compared with its absence. This indicates that there is a
large drain of adenine nucleotides into the ecto-AMP
deaminase shunt-like pathway since its blockade increased
the extracellular levels of endogenous adenosine.
We had previously shown that increasing the levels of
extracellular adenosine, either by maximal inhibition of
adenosine transport or of adenosine deaminase, leads to a
facilitation of the evoked release of acetylcholine from
phrenic motor nerve endings (Correia-de-Sá & Ribeiro,
1996). Accordingly, we now observed that the blockade of
ecto-AMP deaminase also leads to a facilitation of the
evoked release of acetylcholine through the activation of
facilitatory A2A, rather than inhibitory A1, adenosine
receptors. The experiments were carried out in the
presence of a supramaximal concentration of the
adenosine transport inhibitor, NBTI, to rule out the
possibility that deoxycoformycin might be facilitating
acetylcholine release because of its ability to inhibit
adenosine transporters (Rogler-Brown & Parks, 1980).
Deoxycorformycin is also an inhibitor of adenosine
deaminase, and it has previously been suggested that an
ecto-adenosine deaminase activity might be controlling
the removal of extracellular adenosine at the rat
neuromuscular junction (Correia-de-Sá & Ribeiro, 1996).
However, a previous study has shown that the effect of
adenosine deaminase inhibition was not further enhanced
in the presence of a supramaximal concentration of an
adenosine transport blocker (Correia-de-Sá & Ribeiro,
1996). This reinforces our contention that the effect of
deoxycoformycin on ACh release results from the
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inhibition of ecto-AMP deaminase, which has a profound
effect on the extracellular levels of adenosine tonically
controlling the evoked release of acetylcholine. Indeed, if
the levels of adenine nucleotides released during
stimulation were fully converted into adenosine, the
extracellular levels of adenosine would be high enough to
predominantly activate facilitatory A2A receptors,
systematically overtaking the A1 receptor activation
required to restrain superfluous transmitter release at
lower frequencies of nerve stimulation. In addition, fine-
tuning control of cholinergic and peptidergic
neuromodulatory systems, which are regulated by the
balanced activation of adenosine A1 and A2A receptors
(Correia-de-Sá & Ribeiro, 1994a,b; Oliveira et al. 2002),
would also be disrupted. This ecto-AMP deaminase
activity might be critically required at neuromuscular
junctions since the amount of adenine nucleotides
released at these synapses is between one and two orders of
magnitude greater than the levels of extracellular adenine
nucleotides that are released from central nervous system
preparations (cf. Silinsky, 1975; Potter & White, 1980;
Wieraszko et al. 1989; Smith, 1991; Cunha & Sebastião,
1993; Cunha et al. 1996b).
In conclusion, the present results illustrate the functional
importance of ecto-AMP deaminase, an ecto-nucleotidase
activity only found at neuromuscular synapses, for the
controlled formation of extracellular adenosine and proper
functioning of the adenosine neuromodulatory system at
the neuromuscular junction. It remains to be explored if
ecto-AMP deaminase also controls the formation of
adenosine involved in the regulation of functional
hyperaemia (e.g. Proctor & Dubling, 1982) or of the insulin
sensitivity of muscle cells (e.g. Espinal et al. 1983).
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